See more : BlueSword Intelligent Technology Co.,Ltd. (688557.SS) Income Statement Analysis – Financial Results
Complete financial analysis of GenSight Biologics S.A. (GSGTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GenSight Biologics S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Highland Transcend Partners I C (HTPA-WT) Income Statement Analysis – Financial Results
- Semler Scientific, Inc. (SMLR) Income Statement Analysis – Financial Results
- Siemens Energy AG (SMNEY) Income Statement Analysis – Financial Results
- Harrison Vickers and Waterman Inc. (HVCW) Income Statement Analysis – Financial Results
- ITFOR Inc. (4743.T) Income Statement Analysis – Financial Results
GenSight Biologics S.A. (GSGTF)
About GenSight Biologics S.A.
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.27M | 2.58M | 5.28M | 4.39M | 700.00K | 4.35M | 3.70M | 3.00M | 3.56M | 1.10M | 908.44K |
| Cost of Revenue | -1.73M | 0.00 | 0.00 | 0.00 | 0.00 | 315.00K | 224.00K | 202.57K | 138.67K | 0.00 | 0.00 |
| Gross Profit | 3.00M | 2.58M | 5.28M | 4.39M | 700.00K | 4.03M | 3.48M | 2.80M | 3.42M | 1.10M | 908.44K |
| Gross Profit Ratio | 236.78% | 100.00% | 100.00% | 100.00% | 100.00% | 92.75% | 93.95% | 93.25% | 96.10% | 100.00% | 100.00% |
| Research & Development | 19.36M | 18.94M | 22.55M | 21.99M | 28.16M | 29.03M | 18.68M | 18.53M | 10.72M | 6.20M | 2.79M |
| General & Administrative | 6.50M | 8.01M | 5.68M | 2.98M | 2.75M | 4.50M | 3.05M | 1.71M | 4.20M | 695.92K | 424.66K |
| Selling & Marketing | 768.00K | 231.00K | 214.00K | 227.00K | 44.00K | 160.00K | 34.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.27M | 8.24M | 5.89M | 3.21M | 2.80M | 4.66M | 3.09M | 1.71M | 4.20M | 695.92K | 424.66K |
| Other Expenses | 4.34M | 3.24M | 4.95M | 4.13M | 47.00K | -647.00K | 2.23M | 1.78M | -1.26M | -149.78K | -372.02K |
| Operating Expenses | 30.96M | 30.42M | 33.40M | 29.33M | 31.00M | 33.05M | 23.99M | 22.02M | 13.66M | 6.74M | 2.84M |
| Cost & Expenses | 30.96M | 30.42M | 33.40M | 29.33M | 31.00M | 33.05M | 23.99M | 22.02M | 13.66M | 6.74M | 2.84M |
| Interest Income | 0.00 | 2.65M | 2.17M | 89.00K | 407.00K | 0.00 | 0.00 | 26.49K | |||
| Interest Expense | 3.15M | 2.65M | 2.17M | 1.72M | 388.00K | 408.00K | 76.00K | 89.47K | |||
| Depreciation & Amortization | 2.18M | 1.03M | 928.00K | 926.00K | 985.00K | 315.00K | 224.00K | 202.57K | 138.65K | 255.62K | 40.31K |
| EBITDA | -20.89M | -26.44M | -26.83M | -34.13M | -29.31M | -32.73M | -23.77M | -24.81M | -16.39M | -6.49M | -3.63M |
| EBITDA Ratio | -1,648.78% | -1,024.17% | -508.53% | -546.47% | -4,190.43% | -753.11% | -643.17% | -726.07% | -381.01% | -596.79% | -316.35% |
| Operating Income | -29.70M | -27.84M | -28.13M | -24.93M | -30.30M | -33.05M | -23.99M | -22.02M | -13.66M | -6.74M | -2.84M |
| Operating Income Ratio | -2,343.80% | -1,078.04% | -533.09% | -567.46% | -4,328.29% | -760.35% | -648.03% | -733.71% | -383.74% | -611.52% | -312.44% |
| Total Other Income/Expenses | 1.78M | 215.00K | -489.00K | -9.08M | -566.00K | -408.00K | -120.00K | -63.00K | 7.67K | 72.03K | 75.52K |
| Income Before Tax | -27.92M | -27.62M | -28.62M | -34.01M | -30.71M | -33.45M | -24.11M | -22.08M | -13.65M | -6.67M | -2.76M |
| Income Before Tax Ratio | -2,203.39% | -1,069.67% | -542.36% | -774.10% | -4,386.57% | -769.74% | -651.27% | -735.81% | -383.53% | -604.99% | -304.13% |
| Income Tax Expense | -1.70M | 5.00K | 2.00K | 2.00K | 4.00K | 408.00K | 2.00K | 62.98K | -48.98K | -165.22K | -151.33K |
| Net Income | -26.22M | -27.62M | -28.62M | -34.02M | -30.71M | -33.45M | -24.11M | -22.08M | -13.65M | -6.67M | -2.76M |
| Net Income Ratio | -2,069.46% | -1,069.87% | -542.40% | -774.15% | -4,387.14% | -769.74% | -651.32% | -735.81% | -383.53% | -604.99% | -304.13% |
| EPS | -0.54 | -0.60 | -0.63 | -0.97 | -1.08 | -1.37 | -1.10 | -1.36 | -1.21 | -0.75 | -0.32 |
| EPS Diluted | -0.54 | -0.60 | -0.63 | -0.97 | -1.08 | -1.37 | -1.10 | -1.36 | -1.21 | -0.75 | -0.32 |
| Weighted Avg Shares Out | 48.32M | 46.33M | 45.15M | 35.13M | 28.38M | 24.47M | 21.94M | 16.25M | 11.24M | 8.87M | 8.75M |
| Weighted Avg Shares Out (Dil) | 48.32M | 46.33M | 45.15M | 35.13M | 28.38M | 24.47M | 21.94M | 16.25M | 11.24M | 8.87M | 8.75M |
GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the submission of the updated regulatory file...
GenSight Biologics Reports Cash Position as of September 30, 2024, and Provides Business Update
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash...
GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that new scientific data and analyses on...
GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its interim financial results for the first...
GenSight Biologics Launches Newsletter for Retail Investors
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today published the first issue of a company newsletter aimed...
GenSight Biologics Appoints William Monteith to its Board of Directors
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the appointment of William Monteith to...
GenSight Biologics: Annual General Meeting on May 29, 2024
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting...
GenSight Biologics Announces the Filing of its 2023 Universal Registration Document
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2023 Universal Registration...
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash...
Source: https://incomestatements.info
Category: Stock Reports